Moravek


Solutions offered by Moravek include Custom GMP radiolabeling of [14C] APIs – suitable for use in clinical trials Method transfer, development, validation and system suitability under GLP or GMP GLP custom synthesis of labeled and non-labeled compounds Custom synthesis of [14C], [3H], stable labeled and non-labeled compounds – non-GMP Catalog of labeled compounds – 2,000 exceptionally high quality catalog items for standard research Analytical services – NMR of various nuclides, MS, GC/MS, LC/MS, HPLC, UPLC, Karl Fischer and more Stability studies – carried out with NIST traceable temperature tracking and qualified HPLC systems Purification – by various methods including HPLC, flash chromatography and lobar Comprehensive logistics services – storing, dispensing, shipping, chain of custody and temperature tracking Website : www.moravek.com

SARS-CoV-2 - Therapeutic Candidates for Research and Development

SARS-CoV-2, the cause of the COVID-19 epidemic currently affecting all countries in the world, belongs to the genus of betacoronaviruses, which also includes the SARS CoV (2003) and the MERS CoV (2012).

At present, no vaccine or treatment is available to address the COVID-19 pandemic. The SARS-CoV-2 has been the subject of numerous studies that have provided information on its structure, size and protein composition, but there is still room for improvement in understanding its mechanism of interaction with the cells it infects. The current challenge, pending the development of an effective vaccine, is to develop a treatment for the disease that accompanies SARS-CoV-2 infection. Numerous clinical studies are underway or will begin to test various therapeutic candidates for COVID-19.

We offer a wide range of molecules from these therapeutic candidates to support the research and development of a treatment for CoV-2-SARS and COVID-19.

Azithromycin

Duvelisib

Ruxolitinib